NephCure Patient and Youth Summits partnership expands support for rare kidney disease patients

NephCure Patient and Youth Summits partnership expands support for rare kidney disease patients
Climb Bio, Inc. backs NephCure summits

Climb Bio, Inc. announced its sponsorship of the NephCure Patient and Youth Summits, aiming to bring patients, caregivers, researchers, and advocates together to foster collaboration and knowledge sharing in the rare kidney disease community.

The initiative underscores the company’s commitment to accelerating progress for those affected by rare kidney conditions. The summits are expected to provide a platform for learning, connecting, and developing new strategies to support patients and advance research.

Climb Bio, Inc. recently presented initial safety and platelet results from its Phase 1b/2a budoprutug trial in ITP at the EHA congress. The company also discussed its ongoing immunology strategy and future autoimmune research during a Jefferies fireside chat. These events reflect Climb Bio's active engagement in clinical development and research focused on rare diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.